A Phase II Study of Continuous Versus Syncopated Dosing of CC-5013 for the Treatment of Refractory Multiple Myeloma

Phase 2

Completed

• Conditions: Multiple Myeloma

• Registration Number: NCT00051116
• Lead Sponsor: Celgene Corporation

Brief Summary

To evaluate the response rate, response duration, and survival of patients treated with CC-5013 in a chronic dosing schedule versus a syncopated dosing schedule.

Detailed Description

Not available

Study Timeline

• Study Start: 2002-05
• Study First Submitted: 2003-01-03
• Study First Submitted QC: 2003-01-06
• Study First Posted: 2003-01-07
• Primary Completion: 2006-10
• Study Completion: 2006-10
• Status Verified: 2009-09
• Last Update Submitted: 2009-09-22
• Last Update Posted: 2009-09-23

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Trial Locations

Locations (1)

Myeloma Institute University of Arkansas for Medical Sciences; 🇺🇸 Little Rock, Arkansas, United States